A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with
Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
Observational
Observational Model: Case Control, Time Perspective: Prospective
Shouki Bazarbashi, M.D.
Principal Investigator
KFSH & RC
United States: Institutional Review Board
RAC# 2081-068
NCT01311050
January 2009
Name | Location |
---|